adalimumab-afzb (Abrilada) vs infliximab-qbtx (Ixifi)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Rheumatoid Arthritis

Shared mechanism: TNF-alpha · full Rheumatoid Arthritis pipeline

adalimumab-afzb (Abrilada)

Marketed by Pfizer

Approved in Rheumatoid Arthritismonoclonal antibody
Reliable signal

NCT02480153 · Phase 3 · completed

This was a randomized, quadruple-blind, active-controlled Phase 3 trial in 597 patients comparing PF-06410293 with adalimumab-EU on a hard clinical endpoint: ACR20 response at Week 12. The primary equivalence analysis succeeded, with the 95% confidence interval for the response rate difference falling entirely within the prespecified -14% to +14% margin (observed difference -2.98%, 95% CI -10.38% to 4.44%). The large sample size, blinding, active comparator, and met primary endpoint together provide strong evidence of equivalent efficacy.

Reported efficacy

Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12: Period 1: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12: Period 1 (Week 12): Period 1: PF-06410293 68.35% vs Period 1: Adalimumab-EU 71.33% (met)

Result source: NCT02480153

infliximab-qbtx (Ixifi)

Marketed by Pfizer

Approved in Rheumatoid Arthritismonoclonal antibody
Reliable signal

NCT02222493 · Phase 3 · completed

This was a randomized, quadruple-blinded, active-controlled Phase 3 equivalence trial in 650 adults with rheumatoid arthritis taking methotrexate, comparing PF-06438179 with infliximab. The primary endpoint was ACR20 response at Week 14, a clinical disease-activity measure: 61.1% with PF-06438179 versus 63.5% with infliximab, and the reported 95% confidence interval for the difference (-9.92 to 5.11) met the equivalence criterion, indicating no meaningful difference between treatments. This is strong evidence from a well-powered, blinded, controlled trial with a hard clinical endpoint and a met primary comparison.

Reported efficacy

Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 14: Period 1: Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 14: Period 1 (Week 14): Period 1: PF-06438179 198/324 (61.1%) vs Period 1: Infliximab-EU Remicade (INX) 207/326 (63.5%) (met)

Result source: NCT02222493

Results for Rheumatoid Arthritis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointadalimumab-afzb (Abrilada)infliximab-qbtx (Ixifi)
ACR2068.3% vs 71.3%vs Adalimumab-EUwk 12 · n 297NCT02480153
11 other results
  • 86.6% vs 82.2% wk 30 · n 283 · Phase 3 · secondary NCT02480153
  • 83.5% vs 78% wk 26 · n 297 · Phase 3 · secondary NCT02480153
  • 86.6% vs 84.4% wk 26 · n 283 · Phase 3 · secondary NCT02480153
  • 83.4% vs 77.8% wk 36 · n 283 · Phase 3 · secondary NCT02480153
  • 78.1% vs 73.7% wk 18 · n 297 · Phase 3 · secondary NCT02480153
  • 82.3% vs 78.5% wk 44 · n 283 · Phase 3 · secondary NCT02480153
  • 69.4% vs 68% wk 8 · n 297 · Phase 3 · secondary NCT02480153
  • 82.7% vs 79.3% wk 52 · n 283 · Phase 3 · secondary NCT02480153
  • 61.3% vs 59.7% wk 6 · n 297 · Phase 3 · secondary NCT02480153
  • 51.9% vs 52.3% wk 4 · n 297 · Phase 3 · secondary NCT02480153
  • 31.3% vs 32% wk 2 · n 297 · Phase 3 · secondary NCT02480153
61.1% vs 63.5%vs Infliximab-EU Remicade (INX)wk 14 · n 324NCT02222493
12 other results
  • 60.8% vs 64.1% wk 30 · n 324 · Phase 3 · secondary NCT02222493
  • 63.3% vs 65.3% wk 22 · n 324 · Phase 3 · secondary NCT02222493
  • 73.6% vs 70.6% wk 38 · n 280 · Phase 3 · secondary NCT02222493
  • 76.9% vs 70.6% wk 38 · n 143 · Phase 3 · secondary NCT02222493
  • 71.1% vs 68.5% wk 46 · n 280 · Phase 3 · secondary NCT02222493
  • 69.2% vs 68.5% wk 46 · n 143 · Phase 3 · secondary NCT02222493
  • 64.8% vs 65.6% wk 12 · n 324 · Phase 3 · secondary NCT02222493
  • 57.7% vs 61.7% wk 6 · n 324 · Phase 3 · secondary NCT02222493
  • 71.1% vs 64.3% wk 54 · n 280 · Phase 3 · secondary NCT02222493
  • 70.6% vs 64.3% wk 54 · n 143 · Phase 3 · secondary NCT02222493
  • 52.5% vs 58.3% wk 4 · n 324 · Phase 3 · secondary NCT02222493
  • 32.4% vs 37.1% wk 2 · n 324 · Phase 3 · secondary NCT02222493
ACR5062.9% vs 55.6%vs Adalimumab-EUwk 52 · n 283NCT02480153
11 other results
  • 64.3% vs 49.6% wk 44 · n 283 · Phase 3 · secondary NCT02480153
  • 61.1% vs 51.9% wk 36 · n 283 · Phase 3 · secondary NCT02480153
  • 59.7% vs 49.6% wk 30 · n 283 · Phase 3 · secondary NCT02480153
  • 59.6% vs 54.7% wk 26 · n 297 · Phase 3 · secondary NCT02480153
  • 61.8% vs 56.3% wk 26 · n 283 · Phase 3 · secondary NCT02480153
  • 45.1% vs 47% wk 18 · n 297 · Phase 3 · secondary NCT02480153
  • 39.7% vs 39.7% wk 12 · n 297 · Phase 3 · secondary NCT02480153
  • 34% vs 33.3% wk 8 · n 297 · Phase 3 · secondary NCT02480153
  • 27.6% vs 27.3% wk 6 · n 297 · Phase 3 · secondary NCT02480153
  • 17.8% vs 14.3% wk 4 · n 297 · Phase 3 · secondary NCT02480153
  • 8.4% vs 6% wk 2 · n 297 · Phase 3 · secondary NCT02480153
—Not reported
ACR7036.4% vs 31.9%vs Adalimumab-EUwk 52 · n 283NCT02480153
11 other results
  • 38.5% vs 32.6% wk 44 · n 283 · Phase 3 · secondary NCT02480153
  • 36% vs 26.7% wk 36 · n 283 · Phase 3 · secondary NCT02480153
  • 33.9% vs 30.4% wk 30 · n 283 · Phase 3 · secondary NCT02480153
  • 29.6% vs 31% wk 26 · n 297 · Phase 3 · secondary NCT02480153
  • 31.1% vs 30.4% wk 26 · n 283 · Phase 3 · secondary NCT02480153
  • 21.5% vs 22% wk 18 · n 297 · Phase 3 · secondary NCT02480153
  • 16.5% vs 19% wk 12 · n 297 · Phase 3 · secondary NCT02480153
  • 12.5% vs 11.7% wk 8 · n 297 · Phase 3 · secondary NCT02480153
  • 8.1% vs 8.7% wk 6 · n 297 · Phase 3 · secondary NCT02480153
  • 3.7% vs 3.7% wk 4 · n 297 · Phase 3 · secondary NCT02480153
  • 0.7% vs 2% wk 2 · n 297 · Phase 3 · secondary NCT02480153
—Not reported
DAS28-CRP remission—Not reported—Not reported
HAQ-DI, change-0.7 vs -0.7vs Adalimumab-EUwk 52 · n 283NCT02480153
11 other results
  • -0.7 vs -0.7 wk 44 · n 283 · Phase 3 · secondary NCT02480153
  • -0.7 vs -0.7 wk 36 · n 283 · Phase 3 · secondary NCT02480153
  • -0.7 vs -0.7 wk 30 · n 283 · Phase 3 · secondary NCT02480153
  • -0.7 vs -0.7 wk 26 · n 297 · Phase 3 · secondary NCT02480153
  • -0.7 vs -0.7 wk 26 · n 283 · Phase 3 · secondary NCT02480153
  • -0.6 vs -0.6 wk 18 · n 297 · Phase 3 · secondary NCT02480153
  • -0.5 vs -0.5 wk 12 · n 297 · Phase 3 · secondary NCT02480153
  • -0.5 vs -0.5 wk 8 · n 297 · Phase 3 · secondary NCT02480153
  • -0.4 vs -0.5 wk 6 · n 297 · Phase 3 · secondary NCT02480153
  • -0.3 vs -0.4 wk 4 · n 297 · Phase 3 · secondary NCT02480153
  • -0.3 vs -0.3 wk 2 · n 297 · Phase 3 · secondary NCT02480153
—Not reported
Modified Sharp score, change—Not reported—Not reported

ACR20

adalimumab-afzb (Abrilada)
68.3% vs 71.3%vs Adalimumab-EUwk 12 · n 297NCT02480153
11 other results
  • 86.6% vs 82.2% wk 30 · n 283 · Phase 3 · secondary NCT02480153
  • 83.5% vs 78% wk 26 · n 297 · Phase 3 · secondary NCT02480153
  • 86.6% vs 84.4% wk 26 · n 283 · Phase 3 · secondary NCT02480153
  • 83.4% vs 77.8% wk 36 · n 283 · Phase 3 · secondary NCT02480153
  • 78.1% vs 73.7% wk 18 · n 297 · Phase 3 · secondary NCT02480153
  • 82.3% vs 78.5% wk 44 · n 283 · Phase 3 · secondary NCT02480153
  • 69.4% vs 68% wk 8 · n 297 · Phase 3 · secondary NCT02480153
  • 82.7% vs 79.3% wk 52 · n 283 · Phase 3 · secondary NCT02480153
  • 61.3% vs 59.7% wk 6 · n 297 · Phase 3 · secondary NCT02480153
  • 51.9% vs 52.3% wk 4 · n 297 · Phase 3 · secondary NCT02480153
  • 31.3% vs 32% wk 2 · n 297 · Phase 3 · secondary NCT02480153
infliximab-qbtx (Ixifi)
61.1% vs 63.5%vs Infliximab-EU Remicade (INX)wk 14 · n 324NCT02222493
12 other results
  • 60.8% vs 64.1% wk 30 · n 324 · Phase 3 · secondary NCT02222493
  • 63.3% vs 65.3% wk 22 · n 324 · Phase 3 · secondary NCT02222493
  • 73.6% vs 70.6% wk 38 · n 280 · Phase 3 · secondary NCT02222493
  • 76.9% vs 70.6% wk 38 · n 143 · Phase 3 · secondary NCT02222493
  • 71.1% vs 68.5% wk 46 · n 280 · Phase 3 · secondary NCT02222493
  • 69.2% vs 68.5% wk 46 · n 143 · Phase 3 · secondary NCT02222493
  • 64.8% vs 65.6% wk 12 · n 324 · Phase 3 · secondary NCT02222493
  • 57.7% vs 61.7% wk 6 · n 324 · Phase 3 · secondary NCT02222493
  • 71.1% vs 64.3% wk 54 · n 280 · Phase 3 · secondary NCT02222493
  • 70.6% vs 64.3% wk 54 · n 143 · Phase 3 · secondary NCT02222493
  • 52.5% vs 58.3% wk 4 · n 324 · Phase 3 · secondary NCT02222493
  • 32.4% vs 37.1% wk 2 · n 324 · Phase 3 · secondary NCT02222493

ACR50

adalimumab-afzb (Abrilada)
62.9% vs 55.6%vs Adalimumab-EUwk 52 · n 283NCT02480153
11 other results
  • 64.3% vs 49.6% wk 44 · n 283 · Phase 3 · secondary NCT02480153
  • 61.1% vs 51.9% wk 36 · n 283 · Phase 3 · secondary NCT02480153
  • 59.7% vs 49.6% wk 30 · n 283 · Phase 3 · secondary NCT02480153
  • 59.6% vs 54.7% wk 26 · n 297 · Phase 3 · secondary NCT02480153
  • 61.8% vs 56.3% wk 26 · n 283 · Phase 3 · secondary NCT02480153
  • 45.1% vs 47% wk 18 · n 297 · Phase 3 · secondary NCT02480153
  • 39.7% vs 39.7% wk 12 · n 297 · Phase 3 · secondary NCT02480153
  • 34% vs 33.3% wk 8 · n 297 · Phase 3 · secondary NCT02480153
  • 27.6% vs 27.3% wk 6 · n 297 · Phase 3 · secondary NCT02480153
  • 17.8% vs 14.3% wk 4 · n 297 · Phase 3 · secondary NCT02480153
  • 8.4% vs 6% wk 2 · n 297 · Phase 3 · secondary NCT02480153
infliximab-qbtx (Ixifi)
—Not reported

ACR70

adalimumab-afzb (Abrilada)
36.4% vs 31.9%vs Adalimumab-EUwk 52 · n 283NCT02480153
11 other results
  • 38.5% vs 32.6% wk 44 · n 283 · Phase 3 · secondary NCT02480153
  • 36% vs 26.7% wk 36 · n 283 · Phase 3 · secondary NCT02480153
  • 33.9% vs 30.4% wk 30 · n 283 · Phase 3 · secondary NCT02480153
  • 29.6% vs 31% wk 26 · n 297 · Phase 3 · secondary NCT02480153
  • 31.1% vs 30.4% wk 26 · n 283 · Phase 3 · secondary NCT02480153
  • 21.5% vs 22% wk 18 · n 297 · Phase 3 · secondary NCT02480153
  • 16.5% vs 19% wk 12 · n 297 · Phase 3 · secondary NCT02480153
  • 12.5% vs 11.7% wk 8 · n 297 · Phase 3 · secondary NCT02480153
  • 8.1% vs 8.7% wk 6 · n 297 · Phase 3 · secondary NCT02480153
  • 3.7% vs 3.7% wk 4 · n 297 · Phase 3 · secondary NCT02480153
  • 0.7% vs 2% wk 2 · n 297 · Phase 3 · secondary NCT02480153
infliximab-qbtx (Ixifi)
—Not reported

DAS28-CRP remission

adalimumab-afzb (Abrilada)
—Not reported
infliximab-qbtx (Ixifi)
—Not reported

HAQ-DI, change

adalimumab-afzb (Abrilada)
-0.7 vs -0.7vs Adalimumab-EUwk 52 · n 283NCT02480153
11 other results
  • -0.7 vs -0.7 wk 44 · n 283 · Phase 3 · secondary NCT02480153
  • -0.7 vs -0.7 wk 36 · n 283 · Phase 3 · secondary NCT02480153
  • -0.7 vs -0.7 wk 30 · n 283 · Phase 3 · secondary NCT02480153
  • -0.7 vs -0.7 wk 26 · n 297 · Phase 3 · secondary NCT02480153
  • -0.7 vs -0.7 wk 26 · n 283 · Phase 3 · secondary NCT02480153
  • -0.6 vs -0.6 wk 18 · n 297 · Phase 3 · secondary NCT02480153
  • -0.5 vs -0.5 wk 12 · n 297 · Phase 3 · secondary NCT02480153
  • -0.5 vs -0.5 wk 8 · n 297 · Phase 3 · secondary NCT02480153
  • -0.4 vs -0.5 wk 6 · n 297 · Phase 3 · secondary NCT02480153
  • -0.3 vs -0.4 wk 4 · n 297 · Phase 3 · secondary NCT02480153
  • -0.3 vs -0.3 wk 2 · n 297 · Phase 3 · secondary NCT02480153
infliximab-qbtx (Ixifi)
—Not reported

Modified Sharp score, change

adalimumab-afzb (Abrilada)
—Not reported
infliximab-qbtx (Ixifi)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. adalimumab-afzb (Abrilada): 3 of 5 rows · infliximab-qbtx (Ixifi): 3 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricadalimumab-afzb (Abrilada)infliximab-qbtx (Ixifi)
ACR20
responder rate · % of participants
No placebo or comparator arm
83.4% (n=259) @ 78wk*a
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 216 Participants as posted
68.3% (n=126) @ 78wk*b,a
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 86 participants as posted
show 2 more doses
77.8% (n=126) @ 78wk*
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 98 participants as posted
75.9% (n=253) @ 78wk*
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 192 participants as posted
Dropout rate
—Period 1: PF-06410293c
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 3 more results
—Period 2: PF-06410293/PF-06410293
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
—Period 3: PF-06410293/PF-06410293/
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
—
NCT04230213 · Phase 3
—Period 1: PF-06438179
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 5 more results
—Period 2: INX/PF-06438179
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
—Period 2: PF-06438179/PF-06438179
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
—Period 3: INX/INX/PF-06438179
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
—Period 3: INX/PF-06438179/PF-06438
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
—Period 3: PF-06438179/PF-06438179/
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
Discontinued due to AEs
—Period 1: PF-06410293c
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 3 more results
—Period 2: PF-06410293/PF-06410293
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
—Period 3: PF-06410293/PF-06410293/
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
—
NCT04230213 · Phase 3
—Period 1: PF-06438179
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 5 more results
—Period 2: INX/PF-06438179
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
—Period 2: PF-06438179/PF-06438179
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
—Period 3: INX/INX/PF-06438179
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
—Period 3: INX/PF-06438179/PF-06438
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
—Period 3: PF-06438179/PF-06438179/
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
Serious AEs
4%Period 1: PF-06410293c
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 3 more results
1.4%Period 2: PF-06410293/PF-06410293
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
3.5%Period 3: PF-06410293/PF-06410293/
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
1.4%
NCT04230213 · Phase 3
5%Period 1: PF-06438179
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 5 more results
2.8%Period 2: INX/PF-06438179
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
4.6%Period 2: PF-06438179/PF-06438179
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
2.4%Period 3: INX/INX/PF-06438179
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
4.8%Period 3: INX/PF-06438179/PF-06438
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
1.2%Period 3: PF-06438179/PF-06438179/
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
Most frequent reported AEs
c
viral upper respiratory tract infection 7.1%
rheumatoid arthritis 1.7%
nasopharyngitis 0%
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 3 more results
viral upper respiratory tract infection 5.3%
rheumatoid arthritis 1.4%
nasopharyngitis 0.4%
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
nasopharyngitis 5%
rheumatoid arthritis 4.7%
viral upper respiratory tract infection 0.4%
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
sars-cov-2 test positive 8.5%
covid-19 7.5%
erythema 2.8%
NCT04230213 · Phase 3
alanine aminotransferase increased 5.9%
infusion related reaction 5.9%
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 5 more results
infusion related reaction 4.2%
alanine aminotransferase increased 0%
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
infusion related reaction 2.9%
alanine aminotransferase increased 0%
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
alanine aminotransferase increased 0%
infusion related reaction 0%
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
alanine aminotransferase increased 0%
infusion related reaction 0%
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
alanine aminotransferase increased 0%
infusion related reaction 0%
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3

Notes

  1. aPopulation context differs: baseline_threshold differs (hscrp_mg_l>=10, swollen_joint_count>=6, tender_joint_count>=6 versus hscrp_mg_l>=8, swollen_joint_count>=6, tender_joint_count>=6).
  2. bThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  3. cPopulation comparability has not been reviewed for 1 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

adalimumab-afzb (Abrilada)

ACR50 8.4% (n=297) vs 6% (n=300) Adalimumab-EU @ 2wk
responder rate · % of participants
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 25 Participants as posted
show 11 more results
17.8% (n=297) vs 14.3% (n=300) Adalimumab-EU @ 4wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 53 Participants as posted
27.6% (n=297) vs 27.3% (n=300) Adalimumab-EU @ 6wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 82 Participants as posted
34% (n=297) vs 33.3% (n=300) Adalimumab-EU @ 8wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 101 Participants as posted
39.7% (n=297) vs 39.7% (n=300) Adalimumab-EU @ 12wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 118 Participants as posted
45.1% (n=297) vs 47% (n=300) Adalimumab-EU @ 18wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 134 Participants as posted
59.6% (n=297) vs 54.7% (n=300) Adalimumab-EU @ 26wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 177 Participants as posted
61.8% (n=283) vs 56.3% (n=135) Adalimumab-EU @ 26wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 175 Participants as posted
59.7% (n=283) vs 49.6% (n=135) Adalimumab-EU @ 30wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 169 Participants as posted
61.1% (n=283) vs 51.9% (n=135) Adalimumab-EU @ 36wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 173 Participants as posted
64.3% (n=283) vs 49.6% (n=135) Adalimumab-EU @ 44wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 182 Participants as posted
62.9% (n=283) vs 55.6% (n=135) Adalimumab-EU @ 52wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 178 Participants as posted
ACR50 68.3% (n=259) @ 52wk
responder rate · % of participants
No placebo or comparator arm
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 177 Participants as posted
show 4 more results
67.6% (n=259) @ 56wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 175 Participants as posted
68.3% (n=259) @ 66wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 177 Participants as posted
69.1% (n=259) @ 76wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 179 Participants as posted
71.4% (n=259) @ 78wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 185 Participants as posted
ACR70 0.7% (n=297) vs 2% (n=300) Adalimumab-EU @ 2wk
responder rate · % of participants
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 2 Participants as posted
show 11 more results
3.7% (n=297) vs 3.7% (n=300) Adalimumab-EU @ 4wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 11 Participants as posted
8.1% (n=297) vs 8.7% (n=300) Adalimumab-EU @ 6wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 24 Participants as posted
12.5% (n=297) vs 11.7% (n=300) Adalimumab-EU @ 8wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 37 Participants as posted
16.5% (n=297) vs 19% (n=300) Adalimumab-EU @ 12wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 49 Participants as posted
21.5% (n=297) vs 22% (n=300) Adalimumab-EU @ 18wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 64 Participants as posted
29.6% (n=297) vs 31% (n=300) Adalimumab-EU @ 26wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 88 Participants as posted
31.1% (n=283) vs 30.4% (n=135) Adalimumab-EU @ 26wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 88 Participants as posted
33.9% (n=283) vs 30.4% (n=135) Adalimumab-EU @ 30wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 96 Participants as posted
36% (n=283) vs 26.7% (n=135) Adalimumab-EU @ 36wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 102 Participants as posted
38.5% (n=283) vs 32.6% (n=135) Adalimumab-EU @ 44wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 109 Participants as posted
36.4% (n=283) vs 31.9% (n=135) Adalimumab-EU @ 52wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 103 Participants as posted
ACR70 39.8% (n=259) @ 52wk
responder rate · % of participants
No placebo or comparator arm
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 103 Participants as posted
show 4 more results
39% (n=259) @ 56wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 101 Participants as posted
43.2% (n=259) @ 66wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 112 Participants as posted
45.6% (n=259) @ 76wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 118 Participants as posted
49.4% (n=259) @ 78wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 128 Participants as posted
Tender Joint Count -7.5 vs -7.1 Adalimumab-EU joints @ 2wk
absolute change · joints
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 11 more results
-10.2 vs -10.7 Adalimumab-EU joints @ 4wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-12.8 vs -13.1 Adalimumab-EU joints @ 6wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-14.2 vs -15.2 Adalimumab-EU joints @ 8wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-15.4 vs -16.1 Adalimumab-EU joints @ 12wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-16.8 vs -17.3 Adalimumab-EU joints @ 18wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-18.4 vs -19.2 Adalimumab-EU joints @ 26wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-18.4 vs -20.1 Adalimumab-EU joints @ 26wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-19 vs -19.5 Adalimumab-EU joints @ 30wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-18.7 vs -20.1 Adalimumab-EU joints @ 36wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-19.4 vs -21.5 Adalimumab-EU joints @ 44wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-18.9 vs -21 Adalimumab-EU joints @ 52wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
Tender Joint Count -19.3 joints @ 52wk
absolute change · joints
No placebo or comparator arm
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 4 more results
-19.4 joints @ 56wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-19.5 joints @ 66wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-20.6 joints @ 76wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-20.5 joints @ 78wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
Swollen Joint Count -5.7 vs -6.1 Adalimumab-EU joints @ 2wk
absolute change · joints
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 11 more results
-7.7 vs -8.2 Adalimumab-EU joints @ 4wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-9 vs -9.7 Adalimumab-EU joints @ 6wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-9.8 vs -11 Adalimumab-EU joints @ 8wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-10.4 vs -11.8 Adalimumab-EU joints @ 12wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-11.3 vs -13 Adalimumab-EU joints @ 18wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-12.2 vs -13.6 Adalimumab-EU joints @ 26wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-12.2 vs -13.6 Adalimumab-EU joints @ 26wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-12.3 vs -13.3 Adalimumab-EU joints @ 30wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-12.4 vs -14.2 Adalimumab-EU joints @ 36wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-12.8 vs -14.7 Adalimumab-EU joints @ 44wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-12.6 vs -14.2 Adalimumab-EU joints @ 52wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
Swollen Joint Count -12.8 joints @ 52wk
absolute change · joints
No placebo or comparator arm
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 4 more results
-12.9 joints @ 56wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-13 joints @ 66wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-13.3 joints @ 76wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-13.4 joints @ 78wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
Physician Global Assessment -20.7 vs -20.5 Adalimumab-EU score @ 2wk
absolute change · score
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 11 more results
-28.9 vs -29 Adalimumab-EU score @ 4wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-32.6 vs -33 Adalimumab-EU score @ 6wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-35.6 vs -37.1 Adalimumab-EU score @ 8wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-40.4 vs -40.5 Adalimumab-EU score @ 12wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-44.2 vs -44.2 Adalimumab-EU score @ 18wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-47.2 vs -46.5 Adalimumab-EU score @ 26wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-47.7 vs -45.5 Adalimumab-EU score @ 26wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-47.9 vs -46.5 Adalimumab-EU score @ 30wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-47.3 vs -45.4 Adalimumab-EU score @ 36wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-49.1 vs -46.9 Adalimumab-EU score @ 44wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-47.9 vs -48.4 Adalimumab-EU score @ 52wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
Physician Global Assessment -48.9 score @ 52wk
absolute change · score
No placebo or comparator arm
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 4 more results
-50.5 score @ 56wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-49.4 score @ 66wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-50.9 score @ 76wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-52.3 score @ 78wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
Patient Assessment of Arthritis Pain -13.1 vs -13.9 Adalimumab-EU score @ 2wk
absolute change · score
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 11 more results
-18.5 vs -17.4 Adalimumab-EU score @ 4wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-21.9 vs -21.7 Adalimumab-EU score @ 6wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-24.8 vs -25.5 Adalimumab-EU score @ 8wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-28.8 vs -28.5 Adalimumab-EU score @ 12wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-31.5 vs -31.4 Adalimumab-EU score @ 18wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-35.1 vs -33.5 Adalimumab-EU score @ 26wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-35.4 vs -32.4 Adalimumab-EU score @ 26wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-36.3 vs -34.1 Adalimumab-EU score @ 30wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-35.5 vs -34.9 Adalimumab-EU score @ 36wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-38.6 vs -35.7 Adalimumab-EU score @ 44wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-37.4 vs -36.8 Adalimumab-EU score @ 52wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
Patient Assessment of Arthritis Pain -38.1 score @ 52wk
absolute change · score
No placebo or comparator arm
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 4 more results
-39.1 score @ 56wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-39.8 score @ 66wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-41.3 score @ 76wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-43.7 score @ 78wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3

+ 44 further endpoints in the CSV export.

infliximab-qbtx (Ixifi)

ACR50 7.4% (n=324) vs 7.4% (n=326) Infliximab-EU Remicade (INX) @ 2wk
responder rate · % of participants
ACR50 (Week 2)
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 24 participants as posted
ACR50 22.2% (n=324) vs 18.1% (n=326) Infliximab-EU Remicade (INX) @ 4wk
responder rate · % of participants
ACR50 (Week 4)
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 72 participants as posted
ACR50 27.2% (n=324) vs 24.5% (n=326) Infliximab-EU Remicade (INX) @ 6wk
responder rate · % of participants
ACR50 (Week 6)
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 88 participants as posted
ACR50 29.3% (n=324) vs 31% (n=326) Infliximab-EU Remicade (INX) @ 12wk
responder rate · % of participants
ACR50 (Week 12)
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 95 participants as posted
ACR50 35.8% (n=324) vs 33.1% (n=326) Infliximab-EU Remicade (INX) @ 14wk
responder rate · % of participants
ACR50 (Week 14)
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 116 participants as posted
ACR50 38.9% (n=324) vs 35.6% (n=326) Infliximab-EU Remicade (INX) @ 22wk
responder rate · % of participants
ACR50 (Week 22)
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 126 participants as posted
ACR50 38.6% (n=324) vs 40.5% (n=326) Infliximab-EU Remicade (INX) @ 30wk
responder rate · % of participants
ACR50 (Week 30, pre-dose)
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 125 participants as posted
ACR70 1.9% (n=324) vs 1.8% (n=326) Infliximab-EU Remicade (INX) @ 2wk
responder rate · % of participants
ACR70 (Week 2)
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 6 participants as posted
ACR70 6.8% (n=324) vs 4% (n=326) Infliximab-EU Remicade (INX) @ 4wk
responder rate · % of participants
ACR70 (Week 4)
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 22 participants as posted
ACR70 10.2% (n=324) vs 4.9% (n=326) Infliximab-EU Remicade (INX) @ 6wk
responder rate · % of participants
ACR70 (Week 6)
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 33 participants as posted
ACR70 14.2% (n=324) vs 12.3% (n=326) Infliximab-EU Remicade (INX) @ 12wk
responder rate · % of participants
ACR70 (Week 12)
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 46 participants as posted
ACR70 17.3% (n=324) vs 10.1% (n=326) Infliximab-EU Remicade (INX) @ 14wk
responder rate · % of participants
ACR70 (Week 14)
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 56 participants as posted

+ 40 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: adalimumab-afzb (Abrilada)'s landscape · infliximab-qbtx (Ixifi)'s landscape